Physician profile
J Scott Harrison
NPI 1003841073
$8,959.38
in general payments reported to CMS, 2019-2025
40 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $305 · 2021: $1,252 · 2022: $1,688 · 2023: $1,445 · 2024: $1,165 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $973.71 | 2019-2025 | |
| Novo Nordisk INC | $931.35 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $882.05 | 2019-2025 | |
| Amgen INC. | $840.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $711.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $539.34 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $521.12 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $441.16 | 2019-2025 | Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $299.97 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.79 | 2019-2024 | Ofev, Jentadueto, Jardiance |
| Corcept Therapeutics | $221.45 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $213.99 | 2023-2024 | Rexulti |
| Abbott Laboratories | $186.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $180.72 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $174.91 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.